Back

Fusobacterium nucleatum facilitates cetuximab resistance in colorectal cancer via the PI3K/AKT and JAK/STAT3 pathways

Yuan, X.; Han, H.; Li, Y.; Qin, W.; Wang, L.; Yin, H.; Su, B.; Yan Li, Wan Qin, Lu Wang, Han Yin, Beibei Su, and Xianglin Yuan,

2020-12-21 cancer biology
10.1101/2020.12.21.423755 bioRxiv
Show abstract

Infectious pathogens contribute to about 20% of the total tumor burden. Fusobacterium nucleatum (Fn) has been associated with the initiation, progression, and therapy resistance in colorectal cancer (CRC). The over-abundance of Fn has been observed in patients with right-sided CRC than in those with left-sided CRC. While the KRAS/NRAS/BRAF wild-type status of the CRC conferred better response to cetuximab in patients with left-sided CRC than with right-sided CRC. However, treatment failure remains the leading cause of tumor relapse and poor clinical outcome in patients with CRC. Here, we have studied the association of Fn to cetuximab resistance. Our functional studies indicate that Fn facilitates resistance of CRC to cetuximab in vitro and in vivo. Moreover, Fn was found to target the PI3K/AKT and JAK/STAT3 pathways, which altered the response to cetuximab therapy. Therefore, assessing the levels and targeting Fn and the associated signaling pathways may allow modulating the treatment regimen and improve prognoses of CRC patients.

Matching journals

The top 11 journals account for 50% of the predicted probability mass.

1
Scientific Reports
○ 3612 papers in training set
Top 2%
13.4%
Similar papers in this journal
2
Cancers
○ 213 papers in training set
Top 0.5%
8.1%
Similar papers in this journal
3
Frontiers in Oncology
○ 103 papers in training set
Top 0.7%
5.0%
Similar papers in this journal
4
Frontiers in Molecular Biosciences
○ 102 papers in training set
Top 0.1%
4.1%
Similar papers in this journal
5
PLOS ONE
● 5266 papers in training set
Top 32%
4.1%
6
Translational Oncology
○ 21 papers in training set
Top 0.1%
4.1%
Similar papers in this journal
7
Biomedicine & Pharmacotherapy
○ 42 papers in training set
Top 0.2%
3.3%
8
Cancer Medicine
○ 26 papers in training set
Top 0.3%
2.7%
9
Cell Death & Disease
147 papers in training set
Top 1%
2.5%
10
eLife
● 5828 papers in training set
Top 41%
2.4%
11
British Journal of Cancer
○ 49 papers in training set
Top 0.5%
2.4%
50% of probability mass above
12
BMC Cancer
○ 67 papers in training set
Top 1.0%
2.0%
13
International Journal of Cancer
○ 49 papers in training set
Top 0.5%
2.0%
14
International Journal of Molecular Sciences
○ 494 papers in training set
Top 7%
2.0%
15
Gut Microbes
○ 78 papers in training set
Top 0.8%
2.0%
16
Biochemistry and Biophysics Reports
○ 30 papers in training set
Top 0.3%
2.0%
17
Aging
○ 75 papers in training set
Top 0.8%
1.8%
18
Cells
○ 249 papers in training set
Top 3%
1.7%
19
Cell Communication and Signaling
○ 51 papers in training set
Top 0.6%
1.4%
20
Pharmaceuticals
○ 34 papers in training set
Top 0.6%
1.4%
21
iScience
○ 1154 papers in training set
Top 23%
1.4%
22
Molecular Oncology
○ 55 papers in training set
Top 0.9%
1.2%
23
Biochemical Pharmacology
○ 20 papers in training set
Top 0.3%
1.2%
24
Neoplasia
○ 23 papers in training set
Top 0.5%
1.2%
25
Communications Biology
○ 993 papers in training set
Top 28%
0.9%
26
Heliyon
○ 152 papers in training set
Top 7%
0.9%
27
The American Journal of Pathology
○ 32 papers in training set
Top 0.7%
0.9%
28
Frontiers in Pharmacology
○ 111 papers in training set
Top 3%
0.9%
29
Cellular and Molecular Bioengineering
○ 22 papers in training set
Top 0.4%
0.9%
30
Journal of Biological Chemistry
○ 690 papers in training set
Top 9%
0.9%

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.